Serritella Anthony V, Taylor Amy, Haffner Michael C, Abida Wassim, Bryce Alan, Karsh Lawrence I, Tagawa Scott T, Twardowski Przemyslaw, Armstrong Andrew J, Lang Joshua M
University of Wisconsin, Madison, WI, USA.
Fred Hutchinson Cancer Center, Seattle, WA, USA.
Prostate Cancer Prostatic Dis. 2024 Sep 27. doi: 10.1038/s41391-024-00887-z.
BACKGROUND/OBJECTIVES: Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer.
SUBJECTS/METHODS: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.
RESULTS/CONCLUSIONS: In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.
背景/目的：遗憾的是，并非所有转移性去势抵抗性前列腺癌（mCRPC）患者都能接受现有的延长生命的全身治疗，这凸显了优化mCRPC治疗选择的必要性。需要更好的指南来确定前列腺癌的基因检测。
对象/方法：在这份基于专家意见的两部分指南中，我们就利用种系和体细胞检测来检测mCRPC患者的同源重组修复（HRR）改变提供了专家共识意见。本指南由一个多学科专家小组制定，该小组于2023年至2024年召开会议，成员包括医学肿瘤学、泌尿学、放射肿瘤学、病理学、医学基因组学和基础科学领域的代表。
结果/结论：在第二部分中，我们基于对近期III期试验以及随后mCRPC中PARP抑制剂的监管批准的回顾，强调基因检测如何能够带来改善的、延长生命的mCRPC治疗策略。
